Related Experiment Videos
Mitoxantrone therapy in rapidly worsening multiple sclerosis
Y Benesova1, P Stourac, M Beranek
1Department of Neurology, University Hospital, Brno, Czech Republic. benes@fnbrno.cz
Bratislavske Lekarske Listy
|July 20, 2005
Summary
Mitoxantrone therapy showed potential in slowing disability progression for multiple sclerosis (MS) patients. Further research is needed to fully understand its long-term effects and side effects.
Area of Science:
- Neurology
- Immunology
Background:
- Evaluating mitoxantrone (MX) therapy for relapsing remitting and secondary progressive multiple sclerosis (MS).
- Assessing disability progression and side effects of MX treatment.
Purpose of the Study:
- To evaluate the efficacy of mitoxantrone in managing disability progression in MS patients.
- To document the side effect profile of mitoxantrone therapy in this cohort.
Main Methods:
- 33 MS patients (10 male, 23 female, avg age 48.5) with RRMS and SPMS were treated.
- Mitoxantrone (12 mg/m2 monthly) and Solu-Medrol (1000 mg) were administered for six pulses.
- Disability assessed via Expanded Disability Status Scale (EDSS) at baseline and 12 months; Wilcoxon matched pair test used.
Main Results:
- Mitoxantrone therapy was evaluated for its impact on disability progression in MS patients.
- Side effects associated with mitoxantrone treatment were assessed.
- Statistical analysis was performed to determine the significance of observed changes.
Conclusions:
- Mitoxantrone therapy was administered to patients with relapsing remitting and secondary progressive multiple sclerosis.
- The study aimed to evaluate disability progression and side effects of mitoxantrone.
- Further analysis is required to fully interpret the findings regarding mitoxantrone's role in MS management.